Abstract
As MRSA are considered Staphylococcus aureus isolates with oxacillin minimum inhibitory concentration (MIC) of ≥4 mg/L or harboring the mecA gene. However, the presence of mecA does not necessarily lead to oxacillin resistance and mecA gene-carrying isolates may have oxacillin MIC within the susceptible range (≥2 mg/L). During the last few years it has become apparent that oxacillin-susceptible (OS) mecA-positive S. aureus isolates (commonly called OS-MRSA) are rather commonly detected worldwide and may remain undiagnosed using phenotypic susceptibility testing methods. This review will summarize the current reports on OS-MRSA isolations and the underlying mechanisms regulating the expression of oxacillin resistance and also oxacillin susceptibility in mecA-positive S. aureus isolates. As MRSA commonly cause severe infections against which effective therapies are limited, understanding of these mechanisms could enable the identification of new targets for the treatment or reversion of the MRSA phenotype.
Keywords: FemXAB, OS-MRSA, heterogeneity, community-associated MRSA, PBP2a, molecular detection.
Current Pharmaceutical Design
Title:Driving Forces of Mechanisms Regulating Oxacillin-Resistance Phenotypes of MRSA: Truly Oxacillin-Susceptible mecA-Positive Staphylococcus aureus Clinical Isolates also Exist
Volume: 21 Issue: 16
Author(s): Spyros Pournaras, Artur J. Sabat, Hajo Grundmann, Ron Hendrix, Athanasios Tsakris and Alexander W. Friedrich
Affiliation:
Keywords: FemXAB, OS-MRSA, heterogeneity, community-associated MRSA, PBP2a, molecular detection.
Abstract: As MRSA are considered Staphylococcus aureus isolates with oxacillin minimum inhibitory concentration (MIC) of ≥4 mg/L or harboring the mecA gene. However, the presence of mecA does not necessarily lead to oxacillin resistance and mecA gene-carrying isolates may have oxacillin MIC within the susceptible range (≥2 mg/L). During the last few years it has become apparent that oxacillin-susceptible (OS) mecA-positive S. aureus isolates (commonly called OS-MRSA) are rather commonly detected worldwide and may remain undiagnosed using phenotypic susceptibility testing methods. This review will summarize the current reports on OS-MRSA isolations and the underlying mechanisms regulating the expression of oxacillin resistance and also oxacillin susceptibility in mecA-positive S. aureus isolates. As MRSA commonly cause severe infections against which effective therapies are limited, understanding of these mechanisms could enable the identification of new targets for the treatment or reversion of the MRSA phenotype.
Export Options
About this article
Cite this article as:
Pournaras Spyros, Sabat J. Artur, Grundmann Hajo, Hendrix Ron, Tsakris Athanasios and Friedrich W. Alexander, Driving Forces of Mechanisms Regulating Oxacillin-Resistance Phenotypes of MRSA: Truly Oxacillin-Susceptible mecA-Positive Staphylococcus aureus Clinical Isolates also Exist, Current Pharmaceutical Design 2015; 21 (16) . https://dx.doi.org/10.2174/1381612821666150310103754
DOI https://dx.doi.org/10.2174/1381612821666150310103754 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Update on Childhood Brucellosis
Recent Patents on Anti-Infective Drug Discovery Medicinal Use of Lincosamides and Microbial Resistance to Them
Anti-Infective Agents in Medicinal Chemistry Acute Phase Treatment of Pulmonary Embolism
Current Vascular Pharmacology Neuronal Regulation of Aortic Valve Cusps
Current Vascular Pharmacology Methods to Measure Target Site Penetration of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology Aspirin Resistance in Cardiovascular Disease: Pathogenesis, Diagnosis and Clinical Impact
Current Pharmaceutical Design Small Peptide Radiopharmaceuticals in the Imaging of Acute Thrombus
Current Pharmaceutical Design Pharmacological Treatments for Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients
Cardiovascular & Hematological Disorders-Drug Targets Protective Effects of Astaxanthin on Nephrotoxicity in Rats with Induced Renovascular Occlusion
Combinatorial Chemistry & High Throughput Screening Cardiovascular Complications of HIV Infection and Treatment
Cardiovascular & Hematological Agents in Medicinal Chemistry Can Infectious Biofilm be Controlled by Blocking Bacterial Communication?
Medicinal Chemistry Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Antibiotics in Endophthalmitis: Microbiological and Pharmacokinetic Considerations
Current Clinical Pharmacology Development and Validation of a UV-Spectrophotometric Method for Determination of Flucloxacillin Sodium in Capsules
Current Pharmaceutical Analysis Intracellular Life of Coxiella burnetii in Macrophages: Insight into Q Fever Immunopathology
Current Immunology Reviews (Discontinued) Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry